Roberts C R, Longfield J N, Platte R C, Zielmanski K P, Wages J, Fowler A
Department of Diagnostic Retrovirology, Walter Reed Army Institute of Research, Rockville, Md.
Arch Pathol Lab Med. 1994 Dec;118(12):1188-92.
Cases of human immunodeficiency virus type 1 (HIV-1) infection acquired from transfusion of screened antibody-negative blood have been reported since 1986. Recent reports have proposed new combination antibody assays or the addition of HIV-1 p24 antigen testing to enhance the screening of blood donations further. Since antibody testing for HIV-1 began in 1985, 700,000 donor units have been screened at US Army blood donor centers. The US Army blood donor/recipient "lookback" program recently identified two cases of HIV-1 infection that resulted from a screened negative donation. Samples from the implicated unit, as well as from previous donations from the same donor, were available for testing to assess the performance of current screening methods. Sequential donation samples were assayed by five different Food and Drug Administration-approved HIV-1 screening enzyme-linked immunosorbent assays, a Food and Drug Administration-approved Western blot, a recombinant envelope-based enzyme-linked immunosorbent assay, a p24 antigen capture assay, a radioimmunoprecipitation assay, and a polymerase chain reaction. The HIV-1 p24 antigen and genomic RNA material were detected in a donation that was screened as negative by four of the five Food and Drug Administration-licensed screening enzyme-linked immunosorbent assays. Two recipients of transfusion products from this donation became infected with HIV-1. A sample from a prior donation from this donor was negative for HIV-1 by all assays. The status of blood donors who are in the early stages of HIV-1 infection may not be detected by current screening methods. While this is a rare phenomenon, it highlights the need for technologic developments in screening methods to narrow the time between infection and detection. In addition, it emphasizes the need for more effective education and counseling to enhance the utility of self=deferral.
自1986年以来,已有因输注经筛查抗体呈阴性的血液而感染1型人类免疫缺陷病毒(HIV-1)的病例报告。最近的报告提出了新的联合抗体检测方法,或增加HIV-1 p24抗原检测,以进一步加强对献血的筛查。自1985年开始进行HIV-1抗体检测以来,美国陆军献血中心已对70万个献血单位进行了筛查。美国陆军献血者/受血者“追溯”计划最近发现了两例因筛查呈阴性的献血而导致的HIV-1感染病例。来自相关献血单位以及同一献血者之前献血的样本可用于检测,以评估当前筛查方法的性能。对连续献血样本进行了五种不同的经美国食品药品监督管理局批准的HIV-1筛查酶联免疫吸附测定、一种经美国食品药品监督管理局批准的免疫印迹法、一种基于重组包膜的酶联免疫吸附测定、一种p24抗原捕获测定、一种放射免疫沉淀测定和一种聚合酶链反应检测。在一份经五种美国食品药品监督管理局许可的筛查酶联免疫吸附测定中的四种检测为阴性的献血中,检测到了HIV-1 p24抗原和基因组RNA物质。两名接受该献血的输血产品的受血者感染了HIV-1。该献血者之前一次献血的样本经所有检测HIV-1均为阴性。当前的筛查方法可能无法检测出处于HIV-1感染早期阶段的献血者的状况。虽然这是一种罕见现象,但它凸显了筛查方法技术发展的必要性,以缩短感染与检测之间的时间间隔。此外,它强调了进行更有效教育和咨询以提高自我延期效用的必要性。